Skip to main content
KIDS logo

KIDS · Orthopediatrics Corp

Track KIDS — free
$31.74 -0.77 (-2.37%) At close · Nov 20
Market Cap
$828.75M
Shares
26.11M
Volume · Nov 20 153.14K Avg daily vol (3M) 276.7K

Price & Indicators

 

Key stats

Close
$31.74
Fri 20 Nov
Open
$32.12
Fri 20 Nov
Average volume, 30 days
360K
shares a session
Short interest
752K
2.9% of shares · 1.5 days to cover
Day range
$31.56$33.08
Open $32.12 Close $31.74
52-week closing range
$14.64$33.99
Close $31.74 6.6% under the high
Short volume, last session
42%
Last earnings
Oct 27, 2026
Latest filing
10-Q · Oct 28
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly net revenue rises 19% to $72.7 million

OrthoPediatrics reported net revenue of $72.7 million for the three months ended September 30, 2026, up 19% from $61.2 million a year earlier. For the nine months, net revenue rose 16% to $202.5 million, and net cash provided by operating activities was $2.1 million, compared with net cash used of $15.2 million a year earlier.

Revenue $72.66M ▲ 18.6% Net loss $5.93M Diluted EPS -$0.25
Read from the MD&A section
3 source passages
Net revenue increased $11.4 million, or 19%, from $61.2 million for the three months ended September 30, 2025 to $72.7 million for the three months ended September 30, 2026. Net revenue increased $27.8 million, or 16%, from $174.7 million for the nine months ended September 30, 2025 to $202.5 million for the nine months ended September 30, 2026. For the nine months ended September 30, 2026, net cash provided by operating activities was $2.1 million, compared to net cash used in operating activities of $15.2 million for the nine months ended September 30, 2025. Open the document at this passage
Oct 27
Earnings call
Record Q3 revenue of $72.7 million up 19%; full-year guidance raised to $270-$273 million

Third-quarter revenue rose 19% to a record $72.7 million, and full-year 2026 revenue guidance was raised to $270 to $273 million, representing growth of 14 to 16%. Adjusted EBITDA was a record $6.9 million and free cash flow was positive at $1.6 million, while the company reiterated its approximately $25 million adjusted EBITDA guidance.

5 source passages
For the third quarter, we delivered record revenue of $72.7 million, up 19% over the prior year we are raising our full-year revenue guidance to $270 to $273 million, representing growth of 14 to 16% Adjusted EBITDA was a record $6.9 million Free cash flow generated in the third quarter of 2026 was $1.6 million We are also reiterating our adjusted EBITDA guidance of approximately $25 million. Open the document at this passage
Oct 27
Current report 8-K
FY2026 revenue guided to $270.0 to $273.0 million

OrthoPediatrics Corp. presented an investor deck reporting third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier. The company guides full-year 2026 revenue to $270.0 to $273.0 million, 14% to 16% total growth, and adjusted EBITDA of about $25.0 million.

Regulation FD disclosure
4 source passages
FY2026 Revenue $270.0 to $273.0 3Q 2025 3Q 2026 $61.2 $72.7 12% 19% 2026 Total Revenue Growth % 14% to 16% Adjusted EBITDA ~$25.0 Open the document at this passage
Oct 27
Current report 8-K
Third-Quarter Revenue Rises 19% to $72.7 Million; Full-Year Guidance Raised

OrthoPediatrics reported record third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, and a net loss of $5.9 million. Adjusted EBITDA rose to $6.9 million from $6.2 million, and free cash flow was $1.6 million. The company raised its full-year 2026 revenue guidance to $270.0 million to $273.0 million from $265.0 million to $269.0 million.

Financial results
5 source passages
Generated new record high total revenue of $72.7 million for the third quarter of 2026, up 19% from $61.2 million in the third quarter of 2025 Net loss for the third quarter of 2026 was $5.9 million, compared to $11.8 million for the same period last year. Achieved record adjusted EBITDA of $6.9 million in the third quarter of 2026, compared to $6.2 million in the third quarter of 2025 Generated free cash flow of $1.6 million in the third quarter of 2026 Increased full year 2026 revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$264.14M
Trailing 12 months
Net income (TTM)
−$33.88M
Trailing 12 months
Revenue growth YoY
+18.6%
Year over year
Operating margin
-9.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$56.90M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.5%
Year over year · more shares
Price change (1Y)
+88.1%
Trailing year
Short interest
2.9%
Latest settlement · 1.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 27, 2026
Q3 FY26

TL;DR. Third-quarter revenue rose 19% to a record $72.7 million, record adjusted EBITDA reached $6.9 million, free cash flow was positive at $1.6 million, and full-year revenue guidance increased to $270.0 million–$273.0 million while adjusted EBITDA guidance remained approximately $25.0 million. OPSB grew above 20% and product launches progressed, but operating expenses increased, the company remained GAAP unprofitable, and cash, short-term investments and restricted cash declined from year-end 2025.

Bullish
  • + Third-quarter revenue increased 19% to a record $72.7 million, including 19% Trauma & Deformity growth, 18% Scoliosis growth and 18% international growth. new
  • + Adjusted EBITDA reached a record $6.9 million, compared with $6.2 million in the prior-year quarter.
  • + GAAP net loss narrowed to $5.9 million from $11.8 million in the prior-year quarter. new
  • + Free cash flow turned positive at $1.6 million, a $5.0 million year-over-year improvement. new
  • + Full-year revenue guidance was increased to $270.0 million–$273.0 million, while adjusted EBITDA guidance was reiterated at approximately $25.0 million. new
Bearish
  • − Cash, cash equivalents, short-term investments and restricted cash declined to $44.9 million from $62.9 million at December 31, 2025. new
  • − The company remained GAAP unprofitable with a third-quarter net loss of $5.9 million. new
  • − Year-to-date free cash flow was approximately $6 million of usage, requiring approximately $6 million of positive free cash flow in the fourth quarter to reach breakeven or better for 2026. new
  • − Many super-cycle products remained in limited launch and were not yet meaningfully contributing to growth. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +54%
above
Price vs 50-day avg +22%
above
RSI (14) 60
neutral
MACD trend Negative
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +30%
trailing
6-month return +89%
trailing
YTD return +79%
this year
Relative strength +98%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $26 › 200d $21 — 50d above 200d
Institutional flow Accumulating
+18% holders QoQ · +33 funds added
Insider flow Distributing
Net -$15.6M over 90 days · 100% sells
Short interest Falling
2.88% of shares out · ▼ -23.1% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
140 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Fair
Revenue growth +38%
Y/Y
Gross margin 176%
contracting
EPS growth −3%
Y/Y
Free cash flow $-16.0M
Buyback $250.0K
authorized
Balance sheet $82.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 52%
annualized · 1-yr
Max drawdown −27%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 5
Latest guidance · from the 8-K filed Oct 27, 2026
full year 2026
Revenue guidance Raised $270M – $273M
Aug 4, 2026 $265M – $269M changed to Oct 27, 2026 $270M – $273M
prior FY $236.35M midpoint +14.9% Y/Y
2026
Annual set deployment Maintained $10M
Aug 4, 2026 $10M changed to Oct 27, 2026 $10M
Adjusted EBITDA Non-GAAP Maintained $25M
Aug 4, 2026 $25M changed to Oct 27, 2026 $25M
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Sets deployed · full year 2026 $10M
Guided vs delivered · last 5 settled
Revenue full year 2025
guided $233.5M – $234.5M
$236.35M Beat +1.0%
Revenue full year of 2024
guided $200M – $203M
$204.73M Beat +1.6%
Revenue full year 2023
guided $148M – $151M
$148.73M In line
Full year revenue full year 2022
guided $124M – $125M
$122.29M Miss −1.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+54% Bullish
Price vs 50-day avg
+22% Bullish
RSI (14)
60 Neutral
MACD trend
Negative Bearish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $26 › 200d $21 — 50d above 200d
Institutional flow Accumulating
+18% holders QoQ · +33 funds added
Insider flow Distributing
Net -$15.6M over 90 days · 100% sells
Short interest Falling
2.88% of shares out · ▼ -23.1% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
140 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $32 · 88% Range high $34
vs 200-day avg +54% vs 50-day avg +22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP 8.94M Six Months Ended June 30, 2026 —
Cash, cash equivalents, short-term investments and restricted cash $47.9M As of June 30, 2026 —
Free cash flow (non-GAAP) non-GAAP -8.16M Six Months Ended June 30, 2026 —
Free cash flow used non-GAAP $3.1M the second quarter of 2026 —
Helped a record of nearly 46,000 children 46,000 the second quarter of 2026 —
International revenue $15.7M the second quarter of 2026 —
Loss per share, diluted (non-GAAP) non-GAAP -$0.67 Six Months Ended June 30, 2026 —
Sports Medicine/Other revenue $1M the second quarter of 2026 —
U.S. revenue $54.8M the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KIDS
Orthopediatrics Corp
this stock
$828.75M +78.7% +37.9% — 2.9%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
140
% held
66.0%
Net QoQ
+685.9K sh
Top holder
BROWN ADVISORY INC
Held Float
View
Held by Funds
Fund positions
158
View
Short & Settlement
Short Interest Falling
Shares short
751.6K
Days to cover
1.5d
Change
-225.7K sh
View
Short Volume
Short vol %
42%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
330
Value
$7.2K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
45.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$15.6M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Greg Gianforte
Amount
$15.0K–$50.0K
Traded
Jun 18, 2020
View
Financials
Financials
Revenue (FY)
$236.3M
Net income (FY)
$-39.6M
EPS diluted
$-1.69
View
Buybacks
Authorized
$250.0K
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 28, 2026
This year
21

OrthoPediatrics reported net revenue of $72.7 million for the three months ended September 30, 2026, up 19% from $61.2 million a year earlier. For the nine months, net revenue rose 16% to $202.5 million, and net cash provided by operating activities was $2.1 million, compared with net cash used of $15.2 million a year earlier.

View
Proposed Sales
Value
$145.5K
Shares
8.4K
Filed
Mar 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
OrthoPediatrics Announces Full Co…
Published
Nov 9, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
KIDS -1.9% +29.6% +88.8% +2.8% +78.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +6.7% +38.8% +98.0% +11.5% +77.6%

Capital returns

Buyback program · as of Dec 31, 2024
Authorized
$250,000
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1425450 CUSIP 68752L100 13F (30d) 139 filings 123 filers Visit website Investor relations